Test Catalog

Test ID: CHRHB    
Chromosome Analysis, Hematologic Disorders, Blood

Useful For Suggests clinical disorders or settings where the test may be helpful

Assisting in the classification and follow-up of certain malignant hematological disorders when bone marrow is not available

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

This test includes a charge for cell culture of fresh specimens and professional interpretation of results. Analysis charges will be incurred for total work performed, and generally include 2 banded karyograms and the analysis of 20 metaphase cells. If no metaphase cells are available for analysis, no analysis charges will be incurred. If additional analysis work is required, additional charges may be incurred.


This test is not appropriate for detecting constitutional/congenital chromosome abnormalities. If this test is ordered with a reason for referral indicating a concern for a constitutional/congenital chromosome abnormality, the test will be cancelled and CHRCB / Chromosome Analysis, Congenital Disorders, Blood will be added and performed as the appropriate test.


If this test is ordered and the laboratory is informed that the patient is on a COG protocol, this test will be canceled and automatically reordered by the laboratory as COGBL / Chromosome Analysis, Hematologic Disorders, Children’s Oncology Group Enrollment Testing, Blood.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Chromosomal abnormalities play a central role in the pathogenesis, diagnosis, and monitoring of treatment of many hematologic disorders. Whenever possible, it is best to do chromosome studies for neoplastic hematologic disorders on bone marrow. Bone marrow studies are more sensitive and the chances of finding metaphases are about 95%, compared with only a 60% chance for blood studies. When it is not possible to collect bone marrow, chromosome studies on blood may be useful.


When blood cells are cultured in a medium without mitogens, the observation of any chromosomally abnormal clone may be consistent with a neoplastic process.


Conventional chromosome studies of B-cell disorders are not always successful because B-lymphocytes do not proliferate well in cell culture. The agent CpG 7909 (CpG) is a synthetic oligodeoxynucleotide that binds to the Toll-like receptor 9 (TLR9) present on B cells, causing B-cell activation. In the laboratory setting, CpG may be used as a mitogen to stimulate B-cells in patient specimens, thus allowing identification of chromosome abnormalities. CpG stimulation reveals an abnormal karyotype in approximately 80% of patients with of chronic lymphocytic leukemia (CLL), and the karyotype is complex in 20% to 25% of cases. Several studies have reported that increased genetic complexity revealed by CpG-stimulated chromosome studies confers a less favorable time to first treatment, treatment response, and overall survival.


See Laboratory Screening Tests for Suspected Multiple Myeloma in Special Instructions.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

An interpretative report will be provided.

Interpretation Provides information to assist in interpretation of the test results

The presence of an abnormal clone usually indicates a malignant neoplastic process.


The absence of an apparent abnormal clone in blood may result from a lack of circulating abnormal cells and not from an absence of disease.


On rare occasions, the presence of an abnormality may be associated with a congenital abnormality and, thus, not related to a malignant process. When this situation is suspected, follow-up with a medical genetics consultation is recommended.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

We recommend consultation with personnel from the Cytogenetics Laboratory when considering blood studies for hematologic disorders.


Bone marrow specimens are preferred over peripheral blood specimens for the diagnosis of neoplastic hematologic disorders. When peripheral blood must be used, FISH studies may detect some disorders better than conventional chromosome studies.


FISH studies will detect chromosome anomalies with prognostic significance much more often than conventional chromosome studies for:

-Chronic lymphocytic leukemia (CLL)

-Plasma cell proliferative disorders (PCPDs) such as multiple myeloma

-FISH studies also may be superior for other hematological disorders when compared to conventional chromosome studies utilizing blood specimens.


This test is not useful for the following reasons and disorders: multiple miscarriages, infertility, pregnancy loss, multiple congenital anomalies, developmental delay, Down syndrome, Turner syndrome, premature ovarian failure, amenorrhea, ambiguous genitalia, and other congenital abnormalities. The appropriate test for these situations is CHRCB / Chromosome Analysis, Congenital Disorders, Blood.


Interfering factors:


-Cell lysis caused by forcing blood quickly through the needle at collection

-Use of an improper anticoagulant (sodium heparin is best) or improperly mixing the blood with the anticoagulant

-Excessive transport time

-Exposure of the specimen to temperature



-Abnormalities missed due to sampling error

-Subtle structural chromosome abnormalities may be missed occasionally

-Neoplastic cells not dividing or not circulating in the bloodstream

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Dewald GW, Ketterling RP, Wyatt WA, Stupca PJ: Cytogenetic studies in neoplastic hematologic disorders. In Clinical Laboratory Medicine, Second edition. Edited by KD McClatchey. Baltimore, Williams and Wilkens, 2002, pp 658-685

2. Rigolin GM, Cibien F, Martinelli S, et al: Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiological parameters. Blood 2012 Mar 8;119(10):2310-2313

Special Instructions Library of PDFs including pertinent information and forms related to the test